OncoMatch/Clinical Trials/NCT05950139
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
Is NCT05950139 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Peptide vaccine for nsclc stage iv.
Treatment: Peptide vaccine — The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK rearrangement
Documented ALK rearrangement as detected by: (1) fluorescence in situ hybridization (FISH), (2) immuno-histochemistry (IHC), (3) tissue next-generation sequencing (NGS), or (4) circulating tumor DNA (ctDNA) NGS
Required: ALK acquired resistance alterations targeted by the study vaccine
No known presence of the specific ALK acquired resistance alterations targeted by the study vaccine
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: ALK inhibitor (crizotinib, ceritinib, alectinib, brigatinib, lorlatinib) — ongoing
Ongoing treatment with crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib with at least stable disease ≥ 4 months
Cannot have received: cytotoxic chemotherapy
Cytotoxic chemotherapy within 14 days of first dose of study vaccine or concurrent with study vaccine
Cannot have received: anti-neoplastic immunotherapy
Anti-neoplastic immunotherapy within 28 days of first dose of study vaccine or concurrent with study vaccine
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Johns Hopkins University · Baltimore, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05950139 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cytotoxic chemotherapy, anti-neoplastic immunotherapy disqualifies patients from enrollment.
Does this trial require ALK?
Yes, ALK rearrangement is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK acquired resistance alterations targeted by the study vaccine is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages